PCSK9 deficiency rewires heart metabolism and drives heart failure with preserved ejection fraction

Long-Term Evolocumab in Patients With Familial Hypercholesterolemia

(2020) Raul D. Santos et al.   JOURNAL OF THE AMERICAN COLLEGE OF CARDIOLOGY

New Pharmacological Approaches to Target PCSK9

(2020) Alberico L. Catapano et al.   Current Atherosclerosis Reports

PCSK9 Expression in Epicardial Adipose Tissue: Molecular Association with Local Tissue Inflammation

(2020) Elena Dozio et al.   MEDIATORS OF INFLAMMATION

Novel strategies to target PCSK9: beyond monoclonal antibodies

(2019) Nabil G Seidah et al.   CARDIOVASCULAR RESEARCH

Heart Failure in Type 2 Diabetes Mellitus

(2019) Helena C. Kenny et al.   CIRCULATION RESEARCH

Cholesterol metabolism, pancreatic β-cell function and diabetes

(2019) Carla Perego et al.   BIOCHIMICA ET BIOPHYSICA ACTA-MOLECULAR BASIS OF DISEASE

PCSK9 expression in the ischaemic heart and its relationship to infarct size, cardiac function, and development of autophagy

(2018) Zufeng Ding et al.   CARDIOVASCULAR RESEARCH

PCSK9 deficiency reduces insulin secretion and promotes glucose intolerance: the role of the low-density lipoprotein receptor

(2018) Lorenzo Da Dalt et al.   EUROPEAN HEART JOURNAL

Epicardial Adipose Tissue May Mediate Deleterious Effects of Obesity and Inflammation on the Myocardium

(2018) Milton Packer   JOURNAL OF THE AMERICAN COLLEGE OF CARDIOLOGY

PCSK9 deficiency results in increased ectopic fat accumulation in experimental models and in humans

(2017) Andrea Baragetti et al.   European Journal of Preventive Cardiology

Biology of proprotein convertase subtilisin kexin 9: beyond low-density lipoprotein cholesterol lowering

(2016) Giuseppe Danilo Norata et al.   CARDIOVASCULAR RESEARCH

Lipid Use and Misuse by the Heart

(2016) P. Christian Schulze et al.   CIRCULATION RESEARCH

Association Between Low-Density Lipoprotein Cholesterol–Lowering Genetic Variants and Risk of Type 2 Diabetes

(2016) Luca A. Lotta et al.   JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION

Variation in PCSK9 and HMGCR and Risk of Cardiovascular Disease and Diabetes

(2016) Brian A. Ference et al.   NEW ENGLAND JOURNAL OF MEDICINE

PCSK9 Induces CD36 Degradation and Affects Long-Chain Fatty Acid Uptake and Triglyceride Metabolism in Adipocytes and in Mouse LiverSignificance

(2015) Annie Demers et al.   ARTERIOSCLEROSIS THROMBOSIS AND VASCULAR BIOLOGY

Impact of Diabetes on Epidemiology, Treatment, and Outcomes of Patients With Heart Failure

(2015) Alessandra Dei Cas et al.   JACC-Heart Failure

PCSK9

(2014) Nabil G. Seidah et al.   CIRCULATION RESEARCH

Obesity and heart failure: epidemiology, pathophysiology, clinical manifestations, and management

(2014) Martin A. Alpert et al.   Translational Research

Cardiac Metabolism in Heart Failure

(2013) Torsten Doenst et al.   CIRCULATION RESEARCH

Proprotein Convertase Subtilisin/Kexin Type 9 (PCSK9) Can Mediate Degradation of the Low Density Lipoprotein Receptor-Related Protein 1 (LRP-1)

(2013) Maryssa Canuel et al.   PLoS One

Lipid Metabolism and Toxicity in the Heart

(2012) Ira J. Goldberg et al.   Cell Metabolism

Hypertension and Heart Failure

(2011) Richard J. Rodeheffer   CIRCULATION

The VLDL receptor promotes lipotoxicity and increases mortality in mice following an acute myocardial infarction

(2011) Jeanna C. Perman et al.   JOURNAL OF CLINICAL INVESTIGATION

ATGL-mediated fat catabolism regulates cardiac mitochondrial function via PPAR-α and PGC-1

(2011) Guenter Haemmerle et al.   NATURE MEDICINE

Chylomicron- and VLDL-derived Lipids Enter the Heart through Different Pathways

(2010) Kalyani G. Bharadwaj et al.   JOURNAL OF BIOLOGICAL CHEMISTRY

PPARγ-induced cardiolipotoxicity in mice is ameliorated by PPARα deficiency despite increases in fatty acid oxidation

(2010) Ni-Huiping Son et al.   JOURNAL OF CLINICAL INVESTIGATION

Myocardial fatty acid metabolism and cardiac performance in heart failure

(2008) Helena Tuunanen et al.   Current Cardiology Reports